Consequently, our results suggest that targeting TDO2 is a promising strategy for eliminating dormant prostate cancer and preventing tumour recurrence and represents a new therapeutic avenue for targeting recurrent castration-resistant prostate cancer. This evidence concerns the gene TDO2 and prostate carcinoma.